

ARCUS OVERVIEW

NYSE: RCUS

ARCUS
BIOSCIENCES

Global, clinical-stage biopharmaceutical company at the forefront of designing novel combination therapies for cancer

HIGHLY PRODUCTIVE DRUG DISCOVERY

Small Molecules & Antibodies Designed to Be Combined



Targets: CD73, HIF2α, A2a/2b, AXL



Targets: TIGIT, PD-1, CD39

Goal of **1-2**
new molecules advancing
into clinic each year



Accelerated
P 1/2 signal-
seeking &
platform studies

DIVERSE PIPELINE WITH MULTIPLE “SHOTS ON GOAL”

7



Different
molecules
in clinic

3



Registrational Phase
3 trials evaluating a
differentiated, Fc-silent
anti-TIGIT antibody
domvanalimab

24-36



Months for
potential approval
& revenue
generation

\$10B+



Addressable market
opportunity in the U.S.
based on expected
drug treatable patient
population

TOP-TIER PARTNERS FOR STRATEGIC & CLINICAL COLLABORATIONS



Funding:

~\$1.7B

- Holds ~33% equity stake in Arcus
- 50/50 Cost-sharing for certain optioned programs
- Co-development / co-commercialization in the U.S.



STRONG FINANCIAL POSITION & CASH RUNWAY WITH FUNDING INTO 2027



~\$1B cash, cash
equivalents & marketable securities

HQ & RESEARCH CAMPUSES IN BAY AREA



~600
employees

Learn more at investors.arcusbio.com

This summary is provided as of 6/30/24. For a more complete description of our business and risks and uncertainties that may affect forward-looking statements made in this summary, including the statement regarding funding into 2027, please refer to our full corporate presentation and latest Form 10-K and Form 10-Q, which can be found at investors.arcusbio.com.